In synovial sarcoma, Ito et al.have shown that the SYT partner of the SYT-SSX fusion oncoprotein interactswith a HDAC complex, providing a mechanism for specific activity of HDACinhibitors in this disease [25]. Here, HDAC9 is linked to synovial sarcoma.